|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions显示文摘During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2(HER-2) positive breast cancer. Trastuzumab, pertuzumab, adotrastuzumab emtansine and lapatinib are currently food and drug administration(FDA)-approved for the treatment of breast cancer patients with HER-2 overexpressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated informationrelated to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available. | Gonzalo Recondo Jr Enrique Dìaz Canton Màximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Clinical Oncology2014，5，3： | 7 |
| 2 | Intravenous immune globulin suppresses angiogenesis in mice and humans显示文摘Human intravenous immune globulin(IVIg),a purified IgG fraction composed of~60%IgG1 and obtained from the pooled plasma of thousands of donors,is clinically used for a wide range of diseases.The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG(IgG)Fc regions.Recently,we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI,a high-affinity receptor for IgG1.Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases,namely,neovascular age-related macular degeneration,corneal neovascularization,colorectal cancer,fibrosarcoma and peripheral arterial ischemic disease.Angioinhibition was mediated by the Fc region of IVIg,required FcγRI and had similar potency in transgenic mice expressing human FcγRs.Finally,IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities.These data place IVIg,an agent approved by the US Food and Drug Administration,as a novel angioinhibitory drug in doses that are currently administered in the clinical setting.In addition,they raise the possibility of an unintended effect of IVIg on blood vessels. | Reo Yasuma Valeria Cicatiello Takeshi Mizutani Laura Tudisco Younghee Kim Valeria Tarallo Sasha Bogdanovich Yoshio Hirano Nagaraj Kerur Shengjian Li Tetsuhiro Yasuma Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Balamurali K Ambati Sevim Barbasso Helmers Ingrid E Lundberg Ondrej Viklicky Jeanette HW Leusen J Sjef Verbeek Bradley D Gelfand Ana Bastos-Carvalho Sandro De Falco Jayakrishna Ambati | 2016 | Signal Transduction and Targeted Therapy2016，1，1： | 3 |
| 3 | Advances and new perspectives in the treatment of metastatic colon cancer显示文摘During the last decade we have witnessed an unprec-edented outburst of new treatment approaches for the management of metastatic colon cancer.Anti-angio-genic drugs,epidermal growth factor receptor blockers and multi-kinase inhibitors have all resulted in small but consistent improvement in clinical outcomes.However,this progress has paradoxically leaded us into new chal-lenges.In many cases the clinical development was done in parallel and the lack of head-to-head compari-son evolved into circumstances where several valid new'standards of care'are available.Even though desir-able in essence,the availability of many options as well as different possible combinations frequently leaves the busy clinician in the difficult situation of having to choose between one or the other,sometimes without solid evidence to support each decision.In addition,progress never stops and new agents are continuously tested.For these reason this review will try to summa-rize all the clinical trials that constitute the theoretical framework that support our daily practice but will also procure the reader with rational answers to common clinical dilemmas by critically appraising the current literature.Lastly,we will provide with a compilation of promising new agents that may soon become our next line of defense against this deadly disease. | Gonzalo Recondo Jr Enrique Díaz-Cantón Máximo de la Vega Martin Greco Gonzalo Recondo Sr Matias E Valsecchi | 2014 | World Journal of Gastrointestinal Oncology2014，6，7： | 2 |
| 4 | Caesarean scar pregnancy: a review of manage- ment options 显示文摘 | Litwicka K Greco E | 2011 | Curt Opin Obstet Gynecol2011，23，6： | 1 |
| 5 | Late,but not early,paternal effect on human embryo development is related to sperm DNA fragmentation显示文摘 | Tesarik J Greco E Mendoza C | 2004 | Hum Reprod2004，19，3： | 1 |
| 6 | Corrosion of iron in an H2 S - CO2 - H20 system: Corrosion filrm properties on pure iron 显示文摘 | ASardisco J B Wright W B Greco E C | 1963 | Corrosion1963，19，10： | 1 |
| 7 | Caesarean scar pregnancy : a reviewof management options 显示文摘 | Litwicka K Greco E | 2011 | Curr Opin Obstet Gynecol2011，23，6： | 1 |
| 8 | Caesarean scar pregnancy:a review of manangement options显示文摘 | Litwicka K Greco E | 2011 | Curr Opin Obstet Gynecol2011，23，： | 1 |
| 9 | Efficient treatment of infertility due to sperm DNA damage by ICSI with tes ticular spermatozoa显示文摘 | Greco E Scarselli F Iacobelli M | 2005 | Hum Reprod2005，20，1： | 1 |
| 10 | Paternal effects acting during the first cell cycle of human preimplantation development after ICSI显示文摘 | Tesarik J Mendoza C Greco E | 2002 | Hum Reprod2002，17，1： | 1 |
| 11 | Caesarean scar pregnancy:a review of management options显示文摘 | Litwicka K Greco E | 2013 | Curr Opin Obstet Gynecol2013，25，6： | 1 |
| 12 | Importance of cyclophoephamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice 显示文摘 | Pmietti E Greco G Garrone B | 1998 | J Clin Invest1998，101，2： | 1 |
| 13 | Numb is a suppressor of hedgehog signalling and targets glil for itch-dependent ubiquitination 显示文摘 | Di Marcotullio L Ferretti E Greco A | 2006 | Nat Cell Biol2006，8，12： | 1 |
| 14 | Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment 显示文摘 | Greco E Iaeobelli M Rienzi L | 2005 | J Andro12005，26，3： | 1 |
| 15 | Caesarean scar pregnancy:a review ofmanagement options显示文摘 | LITWICKA K GRECO E | 2011 | Curr Opin Obstet Gynecol2011，23，6： | 1 |
| 16 | Successful management of a triplet heterotopic caesarean scar pregnacy after in vitro fertilization-embryo transfer显示文摘 | Litwicka K Greco E Prefumo F | | 0，，01： | 1 |
| 17 | Caesarean scar pregnancy: a review of manage- ment options显示文摘 | Litwicka K Greco E | 2013 | Curt Opin Obstet Gynecol2013，25，6： | 1 |
| 18 | Pre-vention of adhesions in gy-naecologioal en-doscopy 显示文摘 | Nappi C Di Spiezio SA Greco E | 2007 | Hum Reprod Update2007，13，4： | 1 |
| 19 | Increase in RNA and protein synthesis by mitochondria irradiated with helium-ne- on laser 显示文摘 | Greco M Guida G Perlino E | 1989 | Biochem Biophys Res Commun1989，163，3： | 1 |
| 20 | Caesarean scar pregnancy: a review of management options 显示文摘 | Litwieka K Greco E | 2011 | Curr Opin Obstet Gynecol2011，23，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员